13F Pro Quality Score

59.6/100

Rank #913 of 2,879 stocksTOP 50%

View Consumer Staples peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

57.8/100

Profitability

42.9/100

Balance Sheet

68.7/100

Earnings Quality

80.4/100

Free Cash Flow

35.8/100

Institutional Flow

5.9/100

Revenue Scale

99.7/100

Dilution Risk

89.6/100

COR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cencora, Inc. (COR), a Consumer Staples sector company. 13F Pro's AI-powered ranking engine scores COR at 59.6/100 on a 32-signal composite quality model, placing it at rank #913 of 2,879 stocks — the top half of the AI-ranked universe. COR scores in the top quartile across revenue scale (99.7), earnings quality (80.4). Areas of concern include institutional flow (5.9) and free cash flow (35.8), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Cencora, Inc. reports quarterly revenue of $78.4B, net income of $1.6B, an operating margin of 1.5%. Top institutional holders of COR by reported 13-F value include BlackRock,, STATE STREET, FMR, based on the most recent SEC filings. COR trades on the NYSE exchange and files with the SEC under CIK 1140859. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cencora, Inc. directly from SEC EDGAR. Cencora, Inc.'s 13F Pro composite quality score has ranged between 8 and 64 since 2022, currently 59.6 — an improving long-term trajectory across 50 quarterly and live scoring snapshots.

Fun facts about Cencora, Inc.

Quirks, history, and lore behind COR — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. healthcare logistics company · large-cap · listed on NYSE · headquartered in Pennsylvania.
  • 2
    The Numbers
    Annual revenue north of $250 billion, making it one of the largest companies in America by revenue — yet most people have never heard of it.
  • 3
    The History
    Traces its roots to a drug wholesaler founded in the 1870s; after decades of acquisitions it rebranded under its current name in 2023.
  • 4
    The Secret
    It doesn't sell to you — it moves drugs from manufacturers to pharmacies and hospitals, acting as a giant, invisible middleman in the pharmaceutical supply chain.
  • 5
    The Lore
    Formerly known as AmerisourceBergen, it was itself the product of a 2001 mega-merger of two major drug distributors, and it owns a specialty oncology distribution network called ION Solutions.
  • 6
    The Giveaway
    One of the Big Three drug distributors alongside McKesson and Cardinal Health, it rebranded to its current name — a nod to its "centering" care — and trades under the ticker COR.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$78.4B

Net Income

Q2 2026

$1.6B

Free Cash Flow

Q2 2026

$1.2B

Operating Margin

Q2 2026

1.5%

D/E Ratio

Q2 2026

3.71

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+22.6% YoY
$321.33BFY 2025
FY19 $179.59BFY20 $189.89BFY23 $262.17BFY25 $321.33B

Net Income

-11.0% YoY
$1.55BFY 2025
FY19 $855.4MFY20 $-3.41BFY23 $1.75BFY25 $1.55B

Operating Income

+12.3% YoY
$2.63BFY 2025
FY19 $1.11BFY20 $-5.14BFY23 $2.34BFY25 $2.63B

EPS (Diluted)

-6.7% YoY
$7.96FY 2025
FY19 $4.04FY20 $-16.65FY23 $8.53FY25 $7.96

Total Assets

+22.4% YoY
$76.59BFY 2025
FY19 $39.17BFY20 $44.27BFY23 $62.56BFY25 $76.59B

Total Debt

+43.3% YoY
$7.78BFY 2025
FY19 $4.34BFY20 $5.02BFY23 $5.43BFY25 $7.78B

Op. Cash Flow

-0.9% YoY
$3.88BFY 2025
FY19 $2.34BFY20 $2.21BFY23 $3.91BFY25 $3.88B

AI Insight: COR Financial Trends

Net income surged to $1.64B in Q1 2026 while operating margin expanded to 1.46%, but debt jumped 52% to $12.6B.

Operating income grew 51% YoY to $1,143M in Q1 2026 from $756M in Q1 2025, signaling operational leverage.

Total debt increased to $12.6B in Q1 2026 from $8.4B in Q2 2025, the highest in the dataset period.

Equity rebounded to $3.4B in Q1 2026 from $1.5B in Q3 2025, improving balance sheet strength.

Operating cash flow turned negative at -$2.3B in Q4 2025; Q1 2026 recovery to $1.3B requires sustained monitoring.

Q3 2025 posted negative net income of -$340M and minimal op income of $19M; operational volatility persists.

AI Insight: COR Ratio Trends

Q1 2026 profitability surged to 1.5% operating margin and 2.1% net margin, with ROIC stabilizing at 28.6% and leverage improving to 3.71x D/E.

Operating margin expanded to 1.5% in Q1 2026 from 0.0% in Q3 2025, signaling operational recovery after mid-year weakness.

Net profit margin reached 2.1% in Q1 2026, highest in the dataset, up from -0.4% in Q3 2025.

Debt-to-equity improved to 3.71x (TTM) from 7.69x in Q3 2024, indicating sustained deleveraging.

ROIC recovered to 28.6% in Q1 2026 after collapsing to 0.8% in Q3 2025, though below prior-year peaks of 43%.

Q3 2025 saw severe margin compression and negative ROA/ROE; verify whether this reflects seasonal or structural issues.

ROE volatility remains extreme (193.2% in Q1 2026 vs. -90.1% in Q3 2025), suggesting earnings or equity swings.

Get alerted when COR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cencora, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of COR

Put COR on your watchlist

Track score changes the day Cencora, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is COR a good stock to buy?

13F Pro's AI-powered analysis of Cencora, Inc. (COR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Consumer Staples sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for COR are available on the COR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own COR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling COR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cencora, Inc.'s investment landscape.